Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI)...
Gespeichert in:
| Veröffentlicht in: | Genes and immunity 2022-12, Vol.23 (8), p.255-259 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 259 |
|---|---|
| container_issue | 8 |
| container_start_page | 255 |
| container_title | Genes and immunity |
| container_volume | 23 |
| creator | Van Gool, Stefaan W. Makalowski, Jennifer Bitar, Michael Van de Vliet, Peter Schirrmacher, Volker Stuecker, Wilfried |
| description | The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11), |
| doi_str_mv | 10.1038/s41435-022-00162-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9758045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629865163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-36d33c3d1660fbeafcc70a3c9344b363bdb81db061804ae0f18447c2c16b5c883</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwAiyQJTZsAv5PskGiBaaVOmLBsGFjObYz48qxg-1MFd6D98VlSiksWFi27v3uuT46VfUcwdcIkvZNoogSVkOMawgRx_XyoDpGtOE1ow18eO99VD1J6eoGQrx7XB0RhhqCO3Zc_fi8eBO3C-hNvjbGg836K5BeA-u13Vs9S2e_Gw3G2WU7Bi0dsOM4-5B3JsppATmUwhTD3oByonQOpDnu7b6QYQAX788RuLZO13mZDFiv1htQ6DFkE-vZjybvFidz2bA6XYNJZmt8Tk-rR4N0yTy7vU-qLx8_bM7O68tPq4uzd5e1og3NNeGaEEU04hwOvZGDUg2URHWE0p5w0uu-RbqHHLWQSgMH1FLaKKwQ75lqW3JSvT3oTnM_Gq3K7uJATNGOMi4iSCv-7ni7E9uwF13DiiQrAq9uBWL4NpuUxWiTMs5Jb8KcBOa4azlDnBT05T_oVZijL_YEbhjtuo7hplD4QKkYUopmuPsMguImdXFIXZTUxa_UxVKGXty3cTfyO-YCkAOQSstvTfyz-z-yPwGfHLyE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754999527</pqid></control><display><type>article</type><title>Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Van Gool, Stefaan W. ; Makalowski, Jennifer ; Bitar, Michael ; Van de Vliet, Peter ; Schirrmacher, Volker ; Stuecker, Wilfried</creator><creatorcontrib>Van Gool, Stefaan W. ; Makalowski, Jennifer ; Bitar, Michael ; Van de Vliet, Peter ; Schirrmacher, Volker ; Stuecker, Wilfried</creatorcontrib><description>The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11), <complete (12) or not documented (9). Seven patients were treated with surgery/radio(chemo)therapy and subsequent IMI (Group-1); 25 patients were treated with radiochemotherapy followed by maintenance TMZ plus IMI during and after TMZ (Group-2). Age, KPI and extent of resection were not different amongst both groups. The median OS of group-1 patients was 11 m (2 y OS: 0%). Surprisingly the median OS of group-2 patients was 22 m with 2 y OS of 36% (CI95%: 16–57), which was significantly (Log-rank:
p
= 0.0001) different from group-1. The data suggest that addition of IMI after local therapy on its own has no relevant effect on OS in these GBM patients, similar to maintenance TMZ. However, the combination of both TMZ + IMI significantly improved OS.</description><identifier>ISSN: 1476-5470</identifier><identifier>ISSN: 1466-4879</identifier><identifier>EISSN: 1476-5470</identifier><identifier>DOI: 10.1038/s41435-022-00162-y</identifier><identifier>PMID: 35173295</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 631/250/251/1567 ; 631/250/2520 ; 631/250/580 ; Adult ; Antineoplastic Agents, Alkylating - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Brain Neoplasms - genetics ; Brain Neoplasms - therapy ; Brief Communication ; Cancer Research ; Chemoradiotherapy ; Dacarbazine - therapeutic use ; DNA Methylation ; DNA Modification Methylases - genetics ; DNA Modification Methylases - therapeutic use ; DNA Repair Enzymes - genetics ; DNA Repair Enzymes - therapeutic use ; Gene Expression ; Glioblastoma - drug therapy ; Glioblastoma - therapy ; Human Genetics ; Humans ; Immunology ; Immunotherapy ; Isocitrate Dehydrogenase - genetics ; Isocitrate Dehydrogenase - therapeutic use ; Medical prognosis ; Patients ; Retrospective Studies ; Survival ; Temozolomide ; Temozolomide - therapeutic use ; Tumor Suppressor Proteins - genetics</subject><ispartof>Genes and immunity, 2022-12, Vol.23 (8), p.255-259</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-36d33c3d1660fbeafcc70a3c9344b363bdb81db061804ae0f18447c2c16b5c883</citedby><cites>FETCH-LOGICAL-c474t-36d33c3d1660fbeafcc70a3c9344b363bdb81db061804ae0f18447c2c16b5c883</cites><orcidid>0000-0002-4231-154X ; 0000-0002-1434-3659 ; 0000-0002-8102-5968</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35173295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Gool, Stefaan W.</creatorcontrib><creatorcontrib>Makalowski, Jennifer</creatorcontrib><creatorcontrib>Bitar, Michael</creatorcontrib><creatorcontrib>Van de Vliet, Peter</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><creatorcontrib>Stuecker, Wilfried</creatorcontrib><title>Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients</title><title>Genes and immunity</title><addtitle>Genes Immun</addtitle><addtitle>Genes Immun</addtitle><description>The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11), <complete (12) or not documented (9). Seven patients were treated with surgery/radio(chemo)therapy and subsequent IMI (Group-1); 25 patients were treated with radiochemotherapy followed by maintenance TMZ plus IMI during and after TMZ (Group-2). Age, KPI and extent of resection were not different amongst both groups. The median OS of group-1 patients was 11 m (2 y OS: 0%). Surprisingly the median OS of group-2 patients was 22 m with 2 y OS of 36% (CI95%: 16–57), which was significantly (Log-rank:
p
= 0.0001) different from group-1. The data suggest that addition of IMI after local therapy on its own has no relevant effect on OS in these GBM patients, similar to maintenance TMZ. However, the combination of both TMZ + IMI significantly improved OS.</description><subject>13</subject><subject>631/250/251/1567</subject><subject>631/250/2520</subject><subject>631/250/580</subject><subject>Adult</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - therapy</subject><subject>Brief Communication</subject><subject>Cancer Research</subject><subject>Chemoradiotherapy</subject><subject>Dacarbazine - therapeutic use</subject><subject>DNA Methylation</subject><subject>DNA Modification Methylases - genetics</subject><subject>DNA Modification Methylases - therapeutic use</subject><subject>DNA Repair Enzymes - genetics</subject><subject>DNA Repair Enzymes - therapeutic use</subject><subject>Gene Expression</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - therapy</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Isocitrate Dehydrogenase - genetics</subject><subject>Isocitrate Dehydrogenase - therapeutic use</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Temozolomide</subject><subject>Temozolomide - therapeutic use</subject><subject>Tumor Suppressor Proteins - genetics</subject><issn>1476-5470</issn><issn>1466-4879</issn><issn>1476-5470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u1DAUhSMEoqXwAiyQJTZsAv5PskGiBaaVOmLBsGFjObYz48qxg-1MFd6D98VlSiksWFi27v3uuT46VfUcwdcIkvZNoogSVkOMawgRx_XyoDpGtOE1ow18eO99VD1J6eoGQrx7XB0RhhqCO3Zc_fi8eBO3C-hNvjbGg836K5BeA-u13Vs9S2e_Gw3G2WU7Bi0dsOM4-5B3JsppATmUwhTD3oByonQOpDnu7b6QYQAX788RuLZO13mZDFiv1htQ6DFkE-vZjybvFidz2bA6XYNJZmt8Tk-rR4N0yTy7vU-qLx8_bM7O68tPq4uzd5e1og3NNeGaEEU04hwOvZGDUg2URHWE0p5w0uu-RbqHHLWQSgMH1FLaKKwQ75lqW3JSvT3oTnM_Gq3K7uJATNGOMi4iSCv-7ni7E9uwF13DiiQrAq9uBWL4NpuUxWiTMs5Jb8KcBOa4azlDnBT05T_oVZijL_YEbhjtuo7hplD4QKkYUopmuPsMguImdXFIXZTUxa_UxVKGXty3cTfyO-YCkAOQSstvTfyz-z-yPwGfHLyE</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Van Gool, Stefaan W.</creator><creator>Makalowski, Jennifer</creator><creator>Bitar, Michael</creator><creator>Van de Vliet, Peter</creator><creator>Schirrmacher, Volker</creator><creator>Stuecker, Wilfried</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4231-154X</orcidid><orcidid>https://orcid.org/0000-0002-1434-3659</orcidid><orcidid>https://orcid.org/0000-0002-8102-5968</orcidid></search><sort><creationdate>20221201</creationdate><title>Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients</title><author>Van Gool, Stefaan W. ; Makalowski, Jennifer ; Bitar, Michael ; Van de Vliet, Peter ; Schirrmacher, Volker ; Stuecker, Wilfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-36d33c3d1660fbeafcc70a3c9344b363bdb81db061804ae0f18447c2c16b5c883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13</topic><topic>631/250/251/1567</topic><topic>631/250/2520</topic><topic>631/250/580</topic><topic>Adult</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - therapy</topic><topic>Brief Communication</topic><topic>Cancer Research</topic><topic>Chemoradiotherapy</topic><topic>Dacarbazine - therapeutic use</topic><topic>DNA Methylation</topic><topic>DNA Modification Methylases - genetics</topic><topic>DNA Modification Methylases - therapeutic use</topic><topic>DNA Repair Enzymes - genetics</topic><topic>DNA Repair Enzymes - therapeutic use</topic><topic>Gene Expression</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - therapy</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Isocitrate Dehydrogenase - genetics</topic><topic>Isocitrate Dehydrogenase - therapeutic use</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Temozolomide</topic><topic>Temozolomide - therapeutic use</topic><topic>Tumor Suppressor Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Gool, Stefaan W.</creatorcontrib><creatorcontrib>Makalowski, Jennifer</creatorcontrib><creatorcontrib>Bitar, Michael</creatorcontrib><creatorcontrib>Van de Vliet, Peter</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><creatorcontrib>Stuecker, Wilfried</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genes and immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Gool, Stefaan W.</au><au>Makalowski, Jennifer</au><au>Bitar, Michael</au><au>Van de Vliet, Peter</au><au>Schirrmacher, Volker</au><au>Stuecker, Wilfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients</atitle><jtitle>Genes and immunity</jtitle><stitle>Genes Immun</stitle><addtitle>Genes Immun</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>23</volume><issue>8</issue><spage>255</spage><epage>259</epage><pages>255-259</pages><issn>1476-5470</issn><issn>1466-4879</issn><eissn>1476-5470</eissn><abstract>The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11), <complete (12) or not documented (9). Seven patients were treated with surgery/radio(chemo)therapy and subsequent IMI (Group-1); 25 patients were treated with radiochemotherapy followed by maintenance TMZ plus IMI during and after TMZ (Group-2). Age, KPI and extent of resection were not different amongst both groups. The median OS of group-1 patients was 11 m (2 y OS: 0%). Surprisingly the median OS of group-2 patients was 22 m with 2 y OS of 36% (CI95%: 16–57), which was significantly (Log-rank:
p
= 0.0001) different from group-1. The data suggest that addition of IMI after local therapy on its own has no relevant effect on OS in these GBM patients, similar to maintenance TMZ. However, the combination of both TMZ + IMI significantly improved OS.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35173295</pmid><doi>10.1038/s41435-022-00162-y</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4231-154X</orcidid><orcidid>https://orcid.org/0000-0002-1434-3659</orcidid><orcidid>https://orcid.org/0000-0002-8102-5968</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-5470 |
| ispartof | Genes and immunity, 2022-12, Vol.23 (8), p.255-259 |
| issn | 1476-5470 1466-4879 1476-5470 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9758045 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 13 631/250/251/1567 631/250/2520 631/250/580 Adult Antineoplastic Agents, Alkylating - therapeutic use Biomedical and Life Sciences Biomedicine Brain Neoplasms - genetics Brain Neoplasms - therapy Brief Communication Cancer Research Chemoradiotherapy Dacarbazine - therapeutic use DNA Methylation DNA Modification Methylases - genetics DNA Modification Methylases - therapeutic use DNA Repair Enzymes - genetics DNA Repair Enzymes - therapeutic use Gene Expression Glioblastoma - drug therapy Glioblastoma - therapy Human Genetics Humans Immunology Immunotherapy Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - therapeutic use Medical prognosis Patients Retrospective Studies Survival Temozolomide Temozolomide - therapeutic use Tumor Suppressor Proteins - genetics |
| title | Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T12%3A22%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergy%20between%20TMZ%20and%20individualized%20multimodal%20immunotherapy%20to%20improve%20overall%20survival%20of%20IDH1%20wild-type%20MGMT%20promoter-unmethylated%20GBM%20patients&rft.jtitle=Genes%20and%20immunity&rft.au=Van%20Gool,%20Stefaan%20W.&rft.date=2022-12-01&rft.volume=23&rft.issue=8&rft.spage=255&rft.epage=259&rft.pages=255-259&rft.issn=1476-5470&rft.eissn=1476-5470&rft_id=info:doi/10.1038/s41435-022-00162-y&rft_dat=%3Cproquest_pubme%3E2629865163%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754999527&rft_id=info:pmid/35173295&rfr_iscdi=true |